NCT00047320 · OUTCOME
Number of Patients Experiencing Toxic Death
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- During chemotherapy (up to 18 weeks)
What was measured
Toxic death, defined as death predominantly attributable to treatment-related causes.
Analysis population: A total of 102 eligible patients treated with induction chemotherapy were included.
Groups in this outcome
Radiation Therapy (CR From Induction)
Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \> 750/L and platelets \> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy. carboplatin: Given IV etoposide: Given IV ifosfamide: Given IV thiotepa: Given IV adjuvant therapy conventional surgery neoadjuvant therapy peripheral blood stem cell transplantation radiation therapy: craniospinal irradiation
| Group | Source count |
|---|---|
| Radiation Therapy (CR From Induction) | 102 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Radiation Therapy (CR From Induction) | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 102
- units
- Participants
- description
- Toxic death, defined as death predominantly attributable to treatment-related causes.
- groups
- description
- Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \> 750/L and platelets \> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy. carboplatin: Given IV etoposide: Given IV ifosfamide: Given IV thiotepa: Given IV adjuvant therapy conventional surgery neoadjuvant therapy peripheral blood stem cell transplantation radiation therapy: craniospinal irradiation
- id
- OG000
- title
- Radiation Therapy (CR From Induction)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- A total of 102 eligible patients treated with induction chemotherapy were included.
- reporting Status
- POSTED
- time Frame
- During chemotherapy (up to 18 weeks)
- title
- Number of Patients Experiencing Toxic Death
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle